Repaglinide [Usan]
Repaglinide [Usan] Brand names, Repaglinide [Usan] Analogs
Repaglinide [Usan] Brand Names Mixture
- No information avaliable
Repaglinide [Usan] Chemical_Formula
C27H36N2O4
Repaglinide [Usan] RX_link
http://www.rxlist.com/cgi/generic/prandin.htm
Repaglinide [Usan] fda sheet
Repaglinide [Usan] msds (material safety sheet)
Repaglinide [Usan] Synthesis Reference
W. Grell et al., PCT Int. pat. Appl. WO 93 00,337
Repaglinide [Usan] Molecular Weight
452.586 g/mol
Repaglinide [Usan] Melting Point
130-131 oC
Repaglinide [Usan] H2O Solubility
No information avaliable
Repaglinide [Usan] State
Solid
Repaglinide [Usan] LogP
5.798
Repaglinide [Usan] Dosage Forms
Tablet
Repaglinide [Usan] Indication
For the treatment of Type II diabetes mellitus.
Repaglinide [Usan] Pharmacology
Repaglinide is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.
Repaglinide [Usan] Absorption
Rapid (bioavailability is 56%)
Repaglinide [Usan] side effects and Toxicity
LD50 >1 g/kg (rat) (W. Grell)
Repaglinide [Usan] Patient Information
PATIENT INFORMATION
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Repaglinide [Usan] Organisms Affected
Humans and other mammals
![Repaglinide_[Usan]](/images/rx/APRD00439.gif)
